IJTLD OPEN (ISSN: 3005-7590) is open access and fully compliant with Plan S.
Articles submitted to IJTLD OPEN are evaluated solely on scientific merit. IJTLD OPEN has the same values as the IJTLD, with an identical Editorial Board, peer review process and acceptance criteria.
We publish high impact research for the continuing education of academics, clinicians and other health personnel working on respiratory diseases and lung health. Our scope includes translational, clinical, epidemiological and programmatic research to find health solutions for these conditions, including the development of vaccines, diagnostics and medicines for the prevention, management and control of TB and other areas of lung health such as asthma, bronchiectasis, COVID-19, COPD and the hazards of tobacco and air pollution.
IJTLD OPEN is open access and free to read. Also, authors retain copyright and can freely distribute the PDF or upload it to any website. As a consequence, open access articles are highly downloaded and more highly cited.
Click the links below to read our content on PubMed Central, Ingenta.com or see the Table of Contents for each issue.
Authors for both IJTLD and IJTLD OPEN should submit their manuscripts via the same portal and manuscripts will be evaluated solely on scientific merit. Go to Manuscript Central at http://mc.manuscriptcentral.com/ijtld
Before submission, authors should refer to the Instructions for Authors and our Policy Guidelines to check that they have complied with our requirements – see links below:
We invite authors with OA funding to submit their papers (including Editorials, Original Articles, Letters and Case Series) to IJTLD OPEN.
We welcome submissions on the development of vaccines, diagnostics and medicines for the prevention, management and control of TB and all other respiratory diseases.
This includes basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
For all queries please e-mail the Editorial Office
Sponsorship
Supplements and article series are a highly-effective way of highlighting a specific topic to researchers, clinicians and decision makers in respiratory health.
Being an Open Access journal, IJTLD OPEN has no barriers to access and can reach readers in health centres, medical, university and pharmaceutical institutes, along with civil society, patients and carers.
All content will be freely available on Ingenta.com and we will have regular mailings to highlight the latest sponsored content.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD, IJTLD OPEN and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
The impact of COVID-19 on TB: a review of the data
In this recently accepted Review for IJTLD, the authors summarise the evidence available at a country level, identifying broad mechanisms by which COVID-19 may modify TB burden and mitigation efforts.
Tackling TB and COVID-19: US leadership is needed on global health, now more than ever
In the lead up to World TB Day, an article in PHA calls for increased funding and renewed leadership to coordinate the global fight against TB. A relatively small investment in TB control has the potential to transform TB care, saving millions of lives and trillions of dollars in the global economy.
Impact of influenza A co-infection with COVID-19
This study reports on the rate of co-infection with influenza A in a cohort of COVID-19 patients and its impact on the clinical course and outcome.